• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Drops Over 2%; Akouos Shares Spike Higher

    10/18/22 2:43:41 PM ET
    $ADSE
    $AKUS
    $AVEO
    $COSM
    Industrial Specialties
    Consumer Discretionary
    Specialty Chemicals
    Consumer Discretionary
    Get the next $ADSE alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 300 points on Tuesday.

    The Dow traded up 1.02% to 30,492.91 while the NASDAQ rose 0.57% to 10,736.71. The S&P 500 also rose, gaining, 0.94% to 3,712.55.

    Also check this: Fear & Greed Index Moves To 'Fear' Zone After Dow Jumps 550 points


    Leading and Lagging Sectors


    Industrials shares climbed 2.1% on Tuesday. Leading the sector was strength from KULR Technology Group, Inc. (NYSE:KULR) and ADS-TEC Energy PLC (NASDAQ:ADSE).


    In trading on Tuesday, health care shares rose by just 0.4%.


    Top Headline

     

    The Goldman Sachs Group, Inc. (NYSE:GS) reported better-than-expected Q3 results.

    Goldman Sachs Group posted quarterly sales of $11.98 billion, versus market estimates of $11.43 billion.

     

    Equities Trading UP

     

    • Akouos, Inc. (NASDAQ:AKUS) shares shot up 89% to $13.27. Eli Lilly And Co (NYSE:LLY) agreed to acquire Akouos for a 78% premium over Monday’s closing price of $7.01.
    • Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) got a boost, shooting 41% to $14.77 after LG Chem announced it will acquire AVEO Oncology for $15 per share in cash.
    • Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) shares were also up, gaining 24% to $2.34 after the company announced plans to initiate a second clinical trial in Netherton Syndrome patients.


    Equities Trading DOWN

    • Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) shares tumbled 43% to $2.83 after the company announced a pause in new patient enrollment in its Phase 1/2 trial of seclidemstat in Ewing Sarcoma and FET-rearranged sarcomas following the death of a patient.
    • Shares of Cosmos Holdings Inc. (NASDAQ:COSM) were down 47% to $0.0799 after the company announced pricing of a $7.5 million upsized public offering at $0.12 per share.
    • Sierra Metals Inc. (NASDAQ:SMTS) was down, falling 38% to $0.3051 after the company provided a financial and operations update and announced a strategic review process.


    Also check out: Bitcoin, Ethereum Record Gains; Here Are Other Crypto Movers That Should Be On Your Radar Today


    Commodities

    In commodity news, oil traded down 2.2% to $83.56, while gold traded down 0.5% at $1,655.90.


    Silver traded down 0.6% to $18.605 on Tuesday while copper fell 1.6% to $3.3625.


    Euro zone


    European shares closed higher today. The eurozone’s STOXX 600 rose 0.34%, London’s FTSE 100 rose 0.24% while Spain’s IBEX 35 Index jumped 0.72%. The German DAX climbed 0.92%, French CAC 40 rose 0.44% and Italy’s FTSE MIB Index gained 0.93%.

    Passenger car registrations in the European Union surged 9.6% year-over-year to 787,870 units in September. The ZEW Indicator of Economic Sentiment for the Eurozone rose to -59.7 in October versus September's 14-year low level of -60.7, while German ZEW Indicator of Economic Sentiment increased by 2.7 points to -59.2 in October.

    Spanish trade deficit increased to EUR 7.94 billion in August from EUR 3.88 billion in the year-ago month, while Italy reported a trade deficit of EUR 9.57 billion in August versus a year-ago surplus EUR 1.02 billion.

     

    Economics

     

    • Industrial production in the US rose 0.4% from a month ago in September versus a revised 0.1% decline in August and above analysts’ estimates of a 0.1% growth. Manufacturing production climbed 0.4% from a month ago in September.
    • The NAHB housing market index declined for the 10th consecutive month to a reading of 38 in October, down from market estimates of 43.
    • The Treasury International Capital report for August will be released at 4:00 p.m. ET.
    • Minneapolis Fed President Neel Kashkari will speak at 5:30 p.m. ET.


    Check out this: Volatility In Markets Decreases Following Upbeat Bank of America Earnings


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 98,877,880 cases with around 1,090,800 deaths. India confirmed a total of at least 44,632,430 cases and 528,910 deaths, while France reported over 36,268,020 COVID-19 cases with 155,980 deaths. In total, there were at least 630,430,620 cases of COVID-19 worldwide with more than 6,573,170 deaths.

     

    Get the next $ADSE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADSE
    $AKUS
    $AVEO
    $COSM

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    Eli Lilly and Company
    $LLY
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    Eli Lilly and Company
    $LLY
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    Eli Lilly and Company
    $LLY
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    Eli Lilly and Company
    $LLY
    11/13/2025$1165.00Sector Outperform
    Scotiabank
    Eli Lilly and Company
    $LLY
    11/10/2025$1104.00Market Perform → Outperform
    Leerink Partners
    Goldman Sachs Group Inc.
    $GS
    10/21/2025$750.00Overweight → Neutral
    Analyst
    Eli Lilly and Company
    $LLY
    10/20/2025$840.00 → $930.00Outperform
    BMO Capital Markets
    More analyst ratings

    $ADSE
    $AKUS
    $AVEO
    $COSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADSE
    $AKUS
    $AVEO
    $COSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on Eli Lilly with a new price target

    UBS resumed coverage of Eli Lilly with a rating of Buy and set a new price target of $1,250.00

    1/7/26 9:11:47 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eli Lilly upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Eli Lilly from Neutral to Buy and set a new price target of $1,230.00

    12/16/25 8:49:23 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman reiterated coverage on Eli Lilly with a new price target

    Goldman reiterated coverage of Eli Lilly with a rating of Buy and set a new price target of $1,145.00 from $951.00 previously

    12/15/25 10:37:03 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADSE
    $AKUS
    $AVEO
    $COSM
    SEC Filings

    View All

    SEC Form FWP filed by Goldman Sachs Group Inc.

    FWP - GOLDMAN SACHS GROUP INC (0000886982) (Subject)

    2/17/26 5:04:39 PM ET
    $GS
    Investment Bankers/Brokers/Service
    Finance

    SEC Form FWP filed by Goldman Sachs Group Inc.

    FWP - GOLDMAN SACHS GROUP INC (0000886982) (Subject)

    2/17/26 12:56:06 PM ET
    $GS
    Investment Bankers/Brokers/Service
    Finance

    SEC Form FWP filed by Goldman Sachs Group Inc.

    FWP - GOLDMAN SACHS GROUP INC (0000886982) (Subject)

    2/17/26 11:17:45 AM ET
    $GS
    Investment Bankers/Brokers/Service
    Finance

    $ADSE
    $AKUS
    $AVEO
    $COSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Rogers John F.W. sold $15,210,754 worth of shares (15,855 units at $959.37), decreasing direct ownership by 25% to 39,007 units (SEC Form 4)

    4 - GOLDMAN SACHS GROUP INC (0000886982) (Issuer)

    2/13/26 4:23:18 PM ET
    $GS
    Investment Bankers/Brokers/Service
    Finance

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Amendment: EVP & CIDO Rau Diogo was granted 4,599 shares, increasing direct ownership by 21% to 26,397 units (SEC Form 4)

    4/A - ELI LILLY & Co (0000059478) (Issuer)

    2/12/26 4:22:48 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADSE
    $AKUS
    $AVEO
    $COSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $45,000 worth of shares (90,325 units at $0.50), increasing direct ownership by 1% to 8,182,120 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    1/26/26 11:48:12 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    $ADSE
    $AKUS
    $AVEO
    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight

    The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies. Additionally, the launch of emerging therapies such as SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others will further propel the market forward.LAS VEGAS, Feb. 17, 2026 /PRNewswire/ -- Recently published Juvenile Idiopathic Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, juvenile idiopathic arthritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036,

    2/17/26 5:31:00 PM ET
    $ABBV
    $BMY
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cosmos Health Showcases Expanding Brand Portfolio at World Health Expo Dubai 2026

    CHICAGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its participation in World Health Expo Dubai 2026 (formerly Arab Health), one of the world's largest and most influential healthcare exhibitions and conferences. The Expo was held February 9–12, 2026, at the Dubai Exhibition Centre in Expo City Dubai, United Arab Emirates, where Cosmos Health exhibited at Booth SA.A79. The event, which accommodates more than 235,000 visitors and over 4,300 exhibitors from more than 180 countries, brings together healthcare leaders, distributors, manufacturers, and i

    2/17/26 11:25:00 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company

    Milestone achieved in Scribe and Lilly's ongoing collaboration to develop in vivo CRISPR-based therapeutics for neurological and neuromuscular diseases Achievement validates Scribe's technologies and strengthens momentum across its genetic medicine portfolio, including its internal pipeline advances for cardiovascular and metabolic disease Scribe Therapeutics, Inc. (Scribe), a biotechnology company pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives, today announced the achievement of a second success milestone for one of the targets in its collaboration with Eli

    2/17/26 8:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADSE
    $AKUS
    $AVEO
    $COSM
    Financials

    Live finance-specific insights

    View All

    Presidio Announces Proposed $1 Billion Acquisition Financing Facility with Goldman Sachs

    Acquisition Facility expected to accelerate asset acquisition strategy Fort Worth, TX, Feb. 10, 2026 (GLOBE NEWSWIRE) --   Presidio Investment Holdings LLC ("Presidio" or the "Company"), a differentiated oil and gas operator focused on the acquisition and optimization of mature, producing oil and natural gas assets in the United States, and EQV Ventures Acquisition Corp. (NYSE:FTW) ("FTW"), a special purpose acquisition company sponsored by EQV Group, today announced that Presidio has mandated an affiliate of Goldman Sachs (NYSE:GS) to arrange up to $1.0 billion  in potential acquisition financing for Presidio following the completion of its business combination. Goldman Sachs Bank USA

    2/10/26 8:00:00 AM ET
    $EQV
    $FTW
    $GS
    Oil & Gas Production
    Energy
    Investment Bankers/Brokers/Service
    Finance

    Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance

    Revenue in Q4 2025 increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound.Q4 2025 EPS increased by 51% to $7.39 on a reported basis and increased by 42% to $7.54 on a non-GAAP basis, both inclusive of $0.52 of acquired IPR&D charges.Regulatory progress included FDA approval of Kwikpen for tirzepatide and an expanded indication for Jaypirca, and submissions for orforglipron for obesity to regulatory authorities in the U.S. and Japan and for obesity and type 2 diabetes in the EU. Pipeline progress included positive Phase 3 results from Taltz and Zepbound used together for adults with active psoriatic arthritis and obesity, orforglipron for people who switched from in

    2/4/26 6:45:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

    INDIANAPOLIS, Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.   The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into h

    1/21/26 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADSE
    $AKUS
    $AVEO
    $COSM
    Leadership Updates

    Live Leadership Updates

    View All

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

    INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly Neuroscience, and will serve on the Executive Committee. Ho brings more than 20 years of biopharmaceutical experience leading therapeutic development across neurology, rare diseases, immunology, and other areas. Most recently, she served as chief medical officer an

    11/6/25 4:05:00 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly to Acquire Adverum Biotechnologies

    Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve

    10/24/25 8:30:00 AM ET
    $ADVM
    $LLY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ADSE
    $AKUS
    $AVEO
    $COSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quoin Pharmaceuticals Ltd.

    SC 13G/A - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)

    11/14/24 7:23:29 PM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

    SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

    11/14/24 4:50:24 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc.

    SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

    11/14/24 4:38:31 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care